Solaris Pharma

What Solaris Pharma does

Solaris Pharma Corporation is a privately held, US-based specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and 505(b)(2) pharmaceutical products. Founded in 2014 and headquartered in Somerset, New Jersey, the company focuses on therapeutically equivalent formulations of branded reference drugs across multiple dosage forms including topical gels and creams, ophthalmics, sterile products, oral tablets, capsules, and extended-release formulations. Solaris has secured at least 10 FDA ANDA approvals since 2019, including a first-to-market generic of Clindagel in 2021, and has therapeutic coverage spanning dermatology, anti-infectives, cardiovascular, neurology, gastroenterology, and gynecology.

The company's underlying capability is formulation and analytical development for complex dosage forms that have limited generic competition. Manufacturing is outsourced to US-based contract manufacturers, with Cosette Pharmaceuticals serving as the named core manufacturing partner. Distribution flows through pharmaceutical wholesalers and distributors under NDC/UPC codes, with a dedicated National Accounts Manager covering GPOs, ASCs, IDNs, and hospital systems. Solaris earns revenue through one-time product sales of generic formulations to these wholesale and institutional channels, with pricing not publicly disclosed. The company has historically emphasized topical dermatology products but signaled a strategic expansion into oral controlled medications with the May 2026 launch of generic Brivaracetam tablets. Leadership is concentrated under President & CEO Shalin Jani, M.S., who brings 20+ years of experience from Teva, Sandoz, Actavis, and Pfizer.

Name

Solaris Pharma

Legal name

Solaris Pharma Corporation

Website

https://solaris-pharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Solaris Pharma is a privately held US specialty pharmaceutical company that develops and commercializes complex generic formulations—including topical gels, creams, ophthalmics, and oral tablets—across dermatology, anti-infectives, neurology, and other therapeutic areas, distributing through wholesalers and institutional healthcare channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

Keywords

• Complex generic pharmaceuticals
• Topical dermatological products
• 505(b)(2) drug development
• ANDA approvals
• Specialty pharmaceutical manufacturing

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Generic Pharmaceutical Sales: Solaris Pharma generates revenue through the development and commercialization of generic pharmaceutical products. The company develops and supplies generic formulations that are therapeutically equivalent to branded reference products, focusing on products with limited generic competitors and complex dosage forms.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Solaris Pharma is a specialty pharmaceutical company that develops, manufactures (via partners), and commercializes complex generic and 505(b)(2) pharmaceutical products. The portfolio spans topical gels, creams, solutions, suspensions, ophthalmics, tablets, and sterile dosage forms across dermatology, anti-infectives, neurology, cardiovascular, and hormone therapy categories, with products sold through U.S. distributors and institutional accounts.

Product overview

Solaris Pharma is a specialty pharmaceutical company developing and commercializing complex generic and branded pharmaceutical products. The company operates primarily in the topical gel and cream space (historically focused on dermatological treatments such as Clindamycin Phosphate Gels, Tazarotene Gels, Metronidazole Vaginal Gel, and Fluocinolone formulations) while expanding into oral medications (Brivaracetam Tablets for epilepsy, Clarithromycin Tablets, Dicyclomine HCl Capsules, Moxifloxacin Tablets, Neomycin Sulfate Tablets, Nitroglycerin Ointment, and Estradiol Gel). The portfolio includes products across multiple dosage forms including topicals, solutions, suspensions, ophthalmics, and tablets. The company leverages deep technical expertise in advanced formulation and manufacturing capabilities, with a focus on complex generics that have limited competition. Solaris also develops 505(b)(2) products and maintains partnerships with contract manufacturers like Cosette Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

• Clindamycin Phosphate Gel 1% Topical antibiotic gel (1% clindamycin phosphate) for the treatment of acne vulgaris; inhibits bacterial protein synthesis to reduce acne-causing bacteria. Brand equivalent: Clindagel. Sold to distributors, wholesalers, and institutional accounts.
• Metronidazole Vaginal Gel 0.75% Intravaginal antimicrobial gel (0.75% metronidazole) for treatment of bacterial vaginosis in non-pregnant women; disrupts DNA synthesis in susceptible anaerobic bacteria. Supplied in 70g bottle with applicator. Brand equivalent: Metrogel Vaginal.
• Clindamycin Phosphate & Tretinoin Gel 1.2%/0.025% Combination topical gel for acne vulgaris in patients 12 years and older; clindamycin targets acne-causing bacteria while tretinoin promotes skin cell turnover. Available in 30g and 60g tubes. Brand equivalent: Veltin.
• Tazarotene Gel 0.05% Topical retinoid (0.05% tazarotene) for treatment of plaque psoriasis and acne vulgaris; normalizes keratinocyte differentiation and reduces epidermal inflammation. Available in 30g and 100g tubes. Brand equivalent: Tazorac Gel.
• Tazarotene Gel 0.10% Higher-strength topical retinoid (0.10% tazarotene) for plaque psoriasis and acne vulgaris; delivers more intensive therapeutic effect. Available in 30g and 100g tubes. Brand equivalent: Tazorac Gel.
• Neomycin Sulfate Tablets 500mg Aminoglycoside antibiotic oral tablet (500mg) to suppress intestinal bacteria prior to bowel surgery and as adjunctive therapy for hepatic encephalopathy; exerts antimicrobial effect locally within the GI tract due to poor systemic absorption. Supplied as 100-count bottles.
• Estradiol Gel 0.06% Transdermal estrogen therapy (0.06% estradiol) for treatment of moderate to severe vasomotor symptoms associated with menopause; applied once daily to the skin. Supplied in 50g tube. Brand equivalent: Estrogel.
• Brivaracetam Tablets 10mg Antiepileptic tablet (10mg brivaracetam) indicated as adjunctive therapy for partial-onset seizures in patients 4 years and older; binds selectively to synaptic vesicle protein 2A (SV2A). Supplied as 60-count bottles. Brand equivalent: BRIVIACT.
• Brivaracetam Tablets 25mg Antiepileptic tablet (25mg brivaracetam) for partial-onset seizures; binds to SV2A to modulate neurotransmitter release. 60-count bottles. Brand equivalent: BRIVIACT.
• Brivaracetam Tablets 50mg Antiepileptic tablet (50mg brivaracetam) for partial-onset seizures; binds to SV2A to reduce seizure activity. 60-count bottles. Brand equivalent: BRIVIACT.
• Brivaracetam Tablets 75mg Antiepileptic tablet (75mg brivaracetam) for partial-onset seizures; binds to SV2A protein. 60-count bottles. Brand equivalent: BRIVIACT.
• Brivaracetam Tablets 100mg Antiepileptic tablet (100mg brivaracetam) for partial-onset seizures; binds to SV2A to reduce seizure activity. 60-count bottles. Brand equivalent: BRIVIACT.
• Dicyclomine HCl Capsules 10mg Anticholinergic antispasmodic capsule (10mg dicyclomine HCl) for treatment of functional bowel and irritable bowel syndrome; reduces smooth muscle spasms through direct relaxation and anticholinergic activity. Available in 100-count and 1000-count bottles. Brand equivalent: Bentyl.
• Dicyclomine HCl Capsules 20mg Higher-dose anticholinergic antispasmodic capsule (20mg dicyclomine HCl) for IBS symptoms; inhibits muscarinic receptors and relaxes GI smooth muscle. Available in 100-count and 1000-count bottles. Brand equivalent: Bentyl.
• Moxifloxacin Tablets 400mg Fourth-generation fluoroquinolone antibiotic tablet (400mg moxifloxacin) for acute bacterial sinusitis, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, skin infections, and intra-abdominal infections; inhibits bacterial DNA gyrase and topoisomerase IV. 30-count bottles. Brand equivalent: Avelox.
• Nitroglycerin Ointment 0.4% Topical ointment (0.4% nitroglycerin) for treatment of moderate to severe pain associated with chronic anal fissures; relaxes internal anal sphincter through nitric oxide-mediated smooth muscle relaxation. Applied every 12 hours inside the anal canal. 30g tube. Brand equivalent: Rectiv.
• Clarithromycin Tablets 250mg Macrolide antibiotic tablet (250mg clarithromycin) for mild to moderate bacterial infections including respiratory tract infections, skin infections, and H. pylori eradication; inhibits bacterial protein synthesis. 60-count bottles. Brand equivalent: Biaxin.
• Clarithromycin Tablets 500mg Macrolide antibiotic tablet (500mg clarithromycin) for moderate to severe bacterial infections; higher dose for more intensive antibiotic coverage. 60-count bottles. Brand equivalent: Biaxin.
• Clarithromycin Extended-Release Tablets 500mg Once-daily extended-release macrolide antibiotic tablet (500mg clarithromycin) for community-acquired pneumonia and acute maxillary sinusitis; maintains consistent plasma concentrations over 24 hours. 60-count bottles. Brand equivalent: Biaxin XL.

Quantifiable outcome

• First-to-market generic of Clindagel (Clindamycin Phosphate Topical Gel 1%) with immediate day-1 launch capability

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Cosette PharmaceuticalscoreStrategic or Co-development Partner · 23 August 2021Cosette Pharmaceuticals serves as Solaris Pharma's manufacturing partner for certain products. The company manufactured the first generic Clindamycin Phosphate Topical Gel 1% in the United States. Cosette is described as a reliable manufacturing partner with expertise in complex topical products manufactured in the United States.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mayne Pharma: Specialty generic pharmaceutical company with a portfolio that includes topical dermatology, oral solids, and complex generics. Closely comparable to Solaris in therapeutic focus, dosage-form strategy, and customer base of wholesalers and institutional accounts.
• Padagis: Specialty generic pharmaceutical company with strong dermatology and topical franchise (formerly Perrigo's generic Rx business). Directly comparable to Solaris given overlapping dermatology, topical gel/cream, and complex generic product focus.
• Upsher-Smith Laboratories: Private specialty generic pharmaceutical company developing and commercializing complex generics across multiple dosage forms. Comparable to Solaris as a similarly sized, privately held US-based specialty generics competitor with a similar go-to-market model through wholesalers and institutional channels.

Others

• Cosette Pharmaceuticals: US-based specialty pharmaceutical manufacturer and Solaris' core manufacturing partner. Comparable as a peer given overlapping generic/specialty portfolio focus and as an ecosystem participant that shapes Solaris' supply economics.

Broad incumbents

• Endo International: Large specialty pharmaceutical company with significant generics and branded specialty business including dermatology. Comparable as a broad incumbent operating in overlapping therapeutic areas with broader portfolio scale than Solaris.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad portfolio spanning topical, oral, sterile, and specialty dosage forms. Relevant broad incumbent comparable to Solaris across multiple of Solaris' therapeutic categories and dosage forms.
• Sandoz: Global generic and biosimilar pharmaceutical division of Novartis with broad portfolio across dermatology, CNS, and anti-infectives. Comparable as broad incumbent where Solaris' leadership previously held roles and competes for similar complex generic opportunities.
• Viatris: Global pharmaceutical company formed from Mylan and Upjohn with extensive generics and specialty portfolio including dermatology, anti-infectives, and CNS. Comparable as broad incumbent competing for many of the same complex generic opportunities Solaris pursues.
• Taro Pharmaceutical Industries: Generic pharmaceutical manufacturer with strong dermatology and topical portfolio. Comparable broad incumbent in the same topical generic therapeutic categories where Solaris competes (clindamycin, tazarotene, corticosteroids).
• Bausch Health: Branded specialty pharmaceutical company whose Clindagel franchise was the reference product for Solaris' first-to-market generic. Comparable as the brand-side counterpart operating in the same dermatology/topical therapeutic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/solaris-pharma-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solaris Pharma